Miller, Vice President, Immunodermatology Disease Area Leader, Johnson & Johnson, spoke with Dermatology Times about recently published data supporting JNJ-2113's potential in this indication.
Lloyd Miller, MD, PhD
Advertisement
Articles by Lloyd Miller, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
4
Dermatology Conferences and Meetings Calendar: December 2025
5
